Approval of Variation in the Objects of the Initial Public Offer (IPO)
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astonea Labs shareholders have approved a variation in the use of IPO proceeds at an Extraordinary General Meeting on 27th March 2026. Out of ₹8.09 crore in unutilised IPO funds, the company will reallocate ₹6.25 crore (a 16.59% variation) towards acquiring equity shares in Damaira Pharmaceuticals Private Limited. The original IPO prospectus was dated 30th May 2025, and this reallocation represents a strategic investment aimed at expanding into new markets and product lines. Notably, the Bolivia registration allocation of ₹1.29 crore is being reduced to ₹75 lakh, with the rest reallocated. No shareholders dissented, so no exit option is required.
This signals a strategic pivot for Astonea Labs, redirecting unspent IPO money from expansion plans (like Bolivia registration) toward a pharma acquisition. Shareholders should watch for execution of the Damaira Pharma deal within the next 6 months, as it could change the company's growth trajectory and revenue mix.